ZVSA

ZyVersa Therapeutics Inc

0.394
0.019 (5.07%)
Share Name Share Symbol Market Stock Type
ZyVersa Therapeutics Inc ZVSA NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.019 5.07% 0.394 09:56:14
Open Price Low Price High Price Close Price Previous Close
0.38 0.367601 0.39 0.38 0.375
more quote information »

Recent News

Date Time Source Heading
25/5/202323:07GLOBEZyVersa Therapeutics Announces a Publication in Frontiers in..
20/5/202307:28EDGARSecurities Registration: Employee Benefit Plan (s-8)
20/5/202306:52EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
20/5/202306:15GLOBEZyVersa Therapeutics Announces Changes to ZyVersa’s Board of..
15/5/202323:07GLOBEZyVersa Therapeutics Announces Article Published in..
15/5/202320:28EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
13/5/202303:43EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
12/5/202323:07GLOBEZyVersa Therapeutics Reports First Quarter 2023 Corporate..
11/5/202323:07GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate..
09/5/202323:05GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate..
04/5/202323:07GLOBEZyVersa Therapeutics Announces a Publication in Hepatology..
04/5/202306:43EDGARStatement of Ownership (sc 13g)
02/5/202308:30GLOBEZyVersa Therapeutics, Inc. Announces Closing of $11.0..
29/4/202304:10EDGARProspectus Filed Pursuant to Rule 424(b)(4) (424b4)
29/4/202301:20EDGARPost-effective Amendment Filed Solely to Add Exhibits to a..
27/4/202323:07GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at..
27/4/202320:07EDGARNotice of Effectiveness (effect)
26/4/202323:10GLOBEZyVersa Therapeutics, Inc. Announces Pricing of $11.0..
25/4/202323:07GLOBEZyVersa Therapeutics Announces Publication of an Article in..
24/4/202323:07GLOBEZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its..
19/4/202323:07GLOBEZyVersa Therapeutics Announces Article Published in..
13/4/202323:07GLOBEZyVersa Therapeutics Announces Review Article Published in..
12/4/202323:07GLOBEZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on..
12/4/202320:02EDGARSecurities Registration Statement (s-1/a)
11/4/202323:07GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at..
10/4/202323:07GLOBEZyVersa Therapeutics Announces Article Published in Brain..
04/4/202301:22EDGARCurrent Report Filing (8-k)
03/4/202323:05GLOBEZyVersa Therapeutics Reports Fourth Quarter and Year-End..
14/3/202307:30GLOBEZyVersa Therapeutics Reports New Employment Inducement..
08/3/202301:20GLOBEZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its..
02/3/202301:20GLOBEZyVersa Therapeutics to Participate in a Fireside Chat at..
28/2/202301:20GLOBEZyVersa Therapeutics to Participate in a Fireside Chat at..
24/2/202301:20GLOBEZyVersa Therapeutics Announces New Publication in..
15/2/202309:28EDGARAmended Statement of Ownership (sc 13g/a)
15/2/202303:21EDGARAmended Statement of Ownership (sc 13g/a)
14/2/202322:23EDGARStatement of Ownership (sc 13g)
14/2/202301:28EDGARSecurities Registration Statement (s-1/a)
10/2/202306:31EDGARAmended Statement of Ownership (sc 13g/a)
02/2/202308:28EDGARSecurities Registration Statement (s-1/a)
28/1/202308:27EDGARSecurities Registration Statement (s-1)
28/1/202308:11EDGARAmended Current Report Filing (8-k/a)
28/1/202308:06EDGARCurrent Report Filing (8-k)
28/1/202308:00GLOBEZyVersa Therapeutics Reports Inducement Grant to Newly..
26/1/202301:45GLOBEZyVersa Therapeutics to Present at BIO CEO & Investor..
18/1/202304:52EDGARInitial Statement of Beneficial Ownership (3)
12/1/202306:45GLOBEZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at..
06/1/202301:45PRNUSZyVersa Therapeutics Appoints Three New Board Members
04/1/202301:45PRNUSZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology..
30/12/202201:37EDGARNotification Filed by National Security Exchange to Report..
24/12/202209:28EDGARCurrent Report Filing (8-k)
Your Recent History
NASDAQ
ZVSA
ZyVersa Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com

V: D: 20230606 00:25:37